Уноси

Ongoing Strategies to Improve the Management of Upper Respiratory Tract Infections and Reduce Inappropriate Antibiotic Use Particularly Among Lower and Middle-Income Countries: Findings and Implications for the Future (2020-02)

B. Godman, M. Haque, J. McKimm, M. Abu Bakar, J. Sneddoh, J. Wale, S. Campbell, A. Martin, I. Hoxha, V. Abilova, B. Paramadhas, P. Mpinda-Joseph, M. Matome, L. Lovato, I. Sefah, A. Kurdi, S. Opanga, A. Jakupi, Z. Saleem, M. Hassali, D. Kibule, J. Fadare, T. Bochenek, C. Rothe, J. Fraeyman, V. Marković Peković, Љ. Бојанић, N. Schellack, J. Meyer, Z. Matsebula, T. Phuong, B. Thanh, S. Jan, A. Kalungia, S. Matpuri-Ziyowera, M. Sartelli, R. Hill, Ongoing Strategies to Improve the Management of Upper Respiratory Tract Infections and Reduce Inappropriate Antibiotic Use Particularly Among Lower and Middle-Income Countries: Findings and Implications for the Future, CURRENT MEDICAL RESEARCH AND OPINION, Vol. 36, No. 2, pp. 301 - 327, Feb, 2020
Fixed dose drug combinations - are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries (2020-02)

B. Godman, H. McCabe, T. Leong, D. Mueller, A. Martin, I. Hoxha, J. Mwita, G. Rwegerera, A. Massele, J. Costa, R. Nascimento, L. Lovato, K. Tachkov, P. Milushewa, O. Patrick, L. Niba, O. Laius, I. Sefah, S. Abdulsalim, F. Soleymani, L. Achieng, A. Guantai, M. Oluka, A. Jakupi, K. Logviss, M. Hassali, D. Kibule, F. Kalemeera, M. Mubita, I. Mardare, A. Alrasheedy, J. Furst, D. Tomek, V. Marković Peković, T. Phuong, B. Thanh, A. Kalungia, T. Zaranyika, N. Masuka, I. Olaru, J. Wale, R. Hill, A. Kurdi, A. Timoney, S. Campbell, J. Meyer, Fixed dose drug combinations - are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries, Expert Review of Pharmacoeconomics & Outcome Research, Vol. 20, No. 1, pp. 1 - 26, Feb, 2020
Prospective risk assessment of medicine shortages in Europe and Israel: findings and implications (2020-03)

N. Miljković, B. Godman, M. Kovačević, P. Polidori, B. Tubić, Prospective risk assessment of medicine shortages in Europe and Israel: findings and implications, Frontiers in Pharmacology, Vol. Volume 11, pp. 1 - 14, Mar, 2020
Prospective Risk Assessment of Medicine Shortages in Europe and Israel: Findings and Implications. (2020-03)

N. Miljković, B. Godman, M. Kovačević, P. Polidori, L. Tzimis, T. Hoppe-Tichy, M. Saar, I. Antofie, L. Horvath, T. De Rijdt, R. Vida, E. Kkolou, D. Preece, B. Tubić, J. Peppard, A. Martinez, C. Garcia Yubero, R. Haddad, D. Rajinac, P. Zelić, H. Jenzer, F. Tartar, G. Gitler, M. Jeske, M. Davidescu, G. Beraud, D. Kuruc Poje, K. Sakstrup Haag, H. Fischer, I. Sviestina, G. Ljubojević, A. Markestad, V. Vujić-Aleksić, L. Nežić, A. Crkvenčić, J. Linnolahti, B. Ašanin, N. Duborija-Kovačević, T. Bochenek, I. Huys, B. Miljković, Prospective Risk Assessment of Medicine Shortages in Europe and Israel: Findings and Implications., Frontiers in Pharmacology, Vol. 11, No. 357, Mar, 2020
The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures (2021-01)

E. Moorkens, B. Godman, I. Huys, I. Hoxha, A. Malaj, S. Keuerleber, S. Stockinger, S. Mortenhuber, M. Dimitrova, K. Tachkov, L. Vlahović-Palčevski, V. Vlahović-Palčevski, G. Achniotou, J. Slaby, L. Popelkova, K. Kohoutova, D. Bartels, O. Laius, J. Martikainen, G. Selke, V. Kourafalos, E. Magnusson, R. Einarsdottir, R. Adams, R. Joppi, E. Allocati, A. Jakupi, A. Viksna, I. Greičiute-Kuprijanov, P. Vella Bonanno, V. Suttorp, O. Melien, R. Plisko, I. Mardare, D. Meshkov, T. Novakovic, J. Furst, C. Zara, V. Marković Peković, N. Grubiša, G. Befrits, R. Puckett, A. Vulto, The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures, Frontiers in Pharmacology, pp. 1 - 17, Jan, 2021
Variation in the prices of oncology medicines across Europe and the implications for the future (2021-02)

B. Godman, S. Simoens, A. Kurdi, G. Selke, J. Yfantopoulos, A. hill, J. Gulbinovic, A. Martin, A. Timoney, D. Gotham, J. Wale, T. Bochenek, I. Selke Krulichova, E. Allocati, I. Hoxha, A. Malaj, C. Hierlander, A. Nachtnebel, W. Hamelinck, Z. Mitkova, G. Petrova, O. Laius, C. Sermet, I. Langer, R. Joppi, A. Jakupi, E. Poplavski, I. Greičiute-Kuprijanov, P. Vella Bonanno, H. Piepenbrink, V. de Valk, R. Plisko, M. Wladysiuk, V. Marković Peković, I. Mardare, T. Novakovic, M. Parker, J. Furst, D. Tomek, K. Banasova, M. Obach Cortadellas, C. Zara, C. Pontes, M. Juhasz-Haverinen, P. Skiold, S. McTaggart, D. Wong-Rieger, S. Campbell, R. Hill, Variation in the prices of oncology medicines across Europe and the implications for the future, Generics and Biosimilars Initiative Journal, Vol. 10, No. 2, pp. 72 - 82, Feb, 2021
Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications (2021-03)

B. Godman, A. Hill, S. Simoens, G. Selke, I. Selke Krulichova, C. Zampirolli, A. Martin, W. Oortwijn, A. Timoney, L. Gustafsson, L. Vončina, H. Kwon, J. Gulbinovic, D. Gotham, J. Wale, W. da Silva, T. Bochenek, A. Kurdi, E. Allocati, O. Ogunleye, J. Meyer, I. Hoxha, A. Malaj, C. Hierlander, R. Sauremann, W. Hamelinck, G. Petrova, O. Laius, I. Langner, J. Yfantopoulos, R. Joppi, A. Jakupi, I. Greičiute-Kuprijanov, P. Vella Bonanno, H. Piepenbrink, V. de Valk, M. Wladysiuk, V. Marković Peković, I. Mardare, J. Furst, D. Tomek, M. Obach Cortadellas, C. Zara, C. Pontes, S. McTaggart, T. Laba, O. Melien, D. Wong-Rieger, S. Bae, R. Hill, Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications, Expert Review of Pharmacoeconomics & Outcome Research, Vol. 21, No. 4, pp. 527 - 540, Mar, 2021
The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future (2021-06)

B. Godman, M. Haque, T. Leong, E. Allocati, S. Kumar, S. Islam, J. Charan, F. Akter, A. Kurdi, C. Vassalo, M. Abu Bakar, S. Abdur Rahim, N. Sultana, F. Deeba, H. Khan, M. Alam, I. Jahan, Z. Kamal, H. Hasan, M. E-Murshid, S. Nahar, M. Haque, S. Dutta, J. Pallavi Abhayanand, R. Jeet Kaur, G. Rwegerera, R. Nascimento, I. Godoi, M. Irfan, A. Amu, P. Matowa, J. Acolatse, R. Incoom, I. Sefah, J. Acharya, S. Opanga, L. Njeri, D. Kimonge, H. Kwon, S. Bae, K. Khuan, A. Abu Bakar, I. Sani, T. Khan, S. Hussain, Z. Saleem, O. Malande, T. Piloya-Were, R. Gambogi, C. Hernandez Ortiz, L. Alutuli, A. Kalungia, I. Hoxha, V. Marković Peković, Б. Тубић, G. Petrova, K. Tachkov, O. Laius, A. Harsanyi, A. Inotai, A. Jakupi, S. Henkuzens, K. Garuoliene, J. Gulbinovic, M. Wladysiuk, J. Rutkowski, I. Mardare, J. Furst, S. McTaggart, S. MacBride-Stewart, C. Pontes, C. Zara, E. Tagoa, R. Banzi, J. Wale, M. Jakovljevic, The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future, Frontiers in public health, Vol. 9, pp. 1 - 21, Jun, 2021
Strategies to Improve Antimicrobial Utilization with a Special Focus on Developing Countries (2021-06)

B. Godman, A. Egwuenu, M. Haque, O. Malande, N. Schellack, S. Kumar, Z. Saleem, J. Sneddon, I. Hoxha, S. Islam, J. Mwita, R. Nascimento, I. Godoi, L. Niba, A. Amu, J. Acolatse, R. Incoom, I. Sefah, S. Opanga, A. Kurdi, I. Chikowe, F. Khuluza, D. Kibule, O. Ogunleye, A. Olalekan, V. Marković Peković, J. Meyer, A. Alfadl, T. Phuong, A. Kalungia, S. Campbell, A. Pisana, J. Wale, A. Seaton, Strategies to Improve Antimicrobial Utilization with a Special Focus on Developing Countries, Life , Vol. 11, No. 6, pp. 1 - 43, Jun, 2021
Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: Findings and implications (2021-07)

Б. Тубић, V. Marković Peković, С. Јунгић, E. Allocati, B. Godman, Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: Findings and implications, Medicine access @ point of care, Vol. 5, pp. 1 - 7, Jul, 2021
Evidence-based public policy making for medicines across countries: findings and implications for the future (2021-08)

B. Godman, J. Fadare, H. Kwon, C. Zampirolli, A. Kurdi, I. Piassi, D. Kibule, I. Hoxha, S. Opanga, Z. Saleem, T. Bochenek, V. Marković Peković, I. Mardare, A. Kalungia, S. Campbell, E. Allocati, A. Pisana, A. Martin, J. Meyer, Evidence-based public policy making for medicines across countries: findings and implications for the future, Journal of Comparative Effectiveness Research, Vol. 10, No. 12, pp. 1019 - 1052, Aug, 2021
Pharmacists’ clinical knowledge and practice in the safe use of contraceptives: real knowledge vs. self-perception and the implications (2021-08)

А. Golić Jelić, Lj. Tasić, R.Škrbić, V. Marinković, S. Stoisavljević-Šatara, N. Stojaković, V. Marković Peković, B. Godman, Pharmacists’ clinical knowledge and practice in the safe use of contraceptives: real knowledge vs. self-perception and the implications, BMC MEDICAL EDUCATION, Vol. 21, No. 1, pp. 1 - 11, Aug, 2021
Covid-19, healthcare and self-medication issues in resource limited-settings : findings and implications based on experiences in Ghana (2021-09)

I. Sefah, D. Obeng Essah, M. Haque, S. Opanga, S. Kumar, I. Chikowe, D. Kibule, E. Rampambe, A. Kalungia, T. Phuong, Z. Saleem, V. Marković Peković, A. Kurdi, B. Godman, Covid-19, healthcare and self-medication issues in resource limited-settings : findings and implications based on experiences in Ghana, STED Journal, Vol. 11, No. 3, pp. 224 - 233, Sep, 2021
Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications (2021-10)

B. Godman, M. Wladysiuk, S. McTaggart, A. Kurdi, E. Allocati, M. Jakovljevic, F. Kalemeera, I. Hoxha, A. Nachtnebel, R. Sauremann, M. Hinteregger, V. Marković Peković, Б. Тубић, G. Petrova, K. Tachkov, J. Slaby, R. Nejezchlebova, I. Selke Krulichova, O. Laius, G. Selke, I. Langer, A. Harsanyi, A. Inotai, A. Jakupi, S. Henkuzens, K. Garuoliene, J. Gulbinovic, P. Vella Bonanno, J. Rutkowski, S. Ingeberg, O. Melien, I. Mardare, J. Furst, S. McBride-Stewart, C. Holmes, C. Pontes, C. Zara, M. Turu Pedrola, M. Hoffman, V. Kourafalos, A. Pisana, R. Banzi, S. Campbell, B. Wettermark, Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications, BioMed Research International, Vol. 2021, No. Article ID 99961, pp. 1 - 16, Oct, 2021
Progress on the national action plan of Pakistan on antimicrobial resistance (AMR): a narrative review and the implications (2022-01)

Z. Saleem, B. Godman, F. Azhar, A. Kalungia, J. Fadare, S. Opanga, V. Marković Peković, I. Hoxha, A. Saeed, M. Al-Gethamy, A. Haseeb, M. Salman, A. Ali Khan, M. Umer Nadeem, I. Ur Rehman, M. Usman Qamar, A. Amir, A. Ikram, M. Azmi Hassali, Progress on the national action plan of Pakistan on antimicrobial resistance (AMR): a narrative review and the implications, EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, Vol. 20, No. 1, pp. 71 - 93, Jan, 2022
Biosimilars are essential for sustainable healthcare systems; however, key challenges remain as seen with long-acting insulin analogues (2022-03)

B. Godman, B. Tubić, E. Allocati, M. Wladysiuk, S. McTaggart, A. Kurdi, M. Haque, S. McBride-Stewart, F. Kalemeera, A. Massele, I. Hoxha, V. Marković Peković, G. Petrova, K. Tachkov, O. Laius, A. Harsanyi, A. Inotai, A. Jakupi, S. Henkuzens, K. Garuoliene, P. Vella Bonanno, J. Rutkowski, I. Mardare, J. Furst, C. Pontes, C. Zara, M. Turu Pedrola, F. Akter, H. Kwon, A. Martin, R. Banzi, J. Wale, J. Gulbinovic, Biosimilars are essential for sustainable healthcare systems; however, key challenges remain as seen with long-acting insulin analogues, Journal of Applied Pharmaceutical Science, Vol. 12, No. 3, pp. 055 - 072, Mar, 2022
Trends in Antihypertensive Medicine Utilization in the Republic of Srpska, Bosnia and Herzegovina: An Eleven-Year Follow-Up (2022-06)

D. Kalinić, R. Škrbić, D. Vulić, N. Stojaković, S. Stoisavljević-Šatara, M. Stojiljković, V. Marković Peković, A. Golić, N. Pilipović-Broćeta, N. Wong, B. Godman, Trends in Antihypertensive Medicine Utilization in the Republic of Srpska, Bosnia and Herzegovina: An Eleven-Year Follow-Up, Frontiers in Pharmacology, No. 889047, pp. 1 - 12, Jun, 2022
Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries (2022-06)

A. Pisana, B. Wettermark, A. Kurdi, Б. Тубић, C. Pontes, C. Zara, E. Van Ganse, G. Petrova, I. Mardare, J. Furst, M. Roig-Izquierdo, O. Melien, P. Vella Bonanno, R. Banzi, V. Marković Peković, Z. Mitkova, B. Godman, Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries, Frontiers in Pharmacology, No. 873556, pp. 1 - 16, Jun, 2022
Inﬂuence of Recent Initiatives in the Republic of Srpska to Improve Prescribing Efﬁciency; Inﬂuence and Future Direction (2012-08)

V. Marković Peković, B. Godman, R. Škrbić, V. Vlahović-Palčevski, L. Gustafsson, Inﬂuence of Recent Initiatives in the Republic of Srpska to Improve Prescribing Efﬁciency; Inﬂuence and Future Direction, Pharmacoepidemiology and Drug Safety 2012; 21: (Suppl. 3), pp. 57 - 57, Aug, 2012
Essential To Review Health Policy Initiatives When Comparing Utilisation Patterns across Countries? (2012-08)

B. Godman, M. Bennie, S. Campbell, K. Garuoliene, M. Kalaba, V. Marković Peković, V. Vlahović-Palčevski, B. Wettermark, C. Zara, L. Gustafsson, Essential To Review Health Policy Initiatives When Comparing Utilisation Patterns across Countries?, Pharmacoepidemiology and Drug Safety Journal 2012; 21: (Suppl. 3), pp. 56 - 56, Aug, 2012

Уноси

Ongoing Strategies to Improve the Management of Upper Respiratory Tract Infections and Reduce Inappropriate Antibiotic Use Particularly Among Lower and Middle-Income Countries: Findings and Implications for the Future (2020-02)

Fixed dose drug combinations - are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries (2020-02)

Prospective risk assessment of medicine shortages in Europe and Israel: findings and implications (2020-03)

Prospective Risk Assessment of Medicine Shortages in Europe and Israel: Findings and Implications. (2020-03)

The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures (2021-01)

Variation in the prices of oncology medicines across Europe and the implications for the future (2021-02)

Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications (2021-03)

The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future (2021-06)

Strategies to Improve Antimicrobial Utilization with a Special Focus on Developing Countries (2021-06)

Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: Findings and implications (2021-07)

Evidence-based public policy making for medicines across countries: findings and implications for the future (2021-08)

Pharmacists’ clinical knowledge and practice in the safe use of contraceptives: real knowledge vs. self-perception and the implications (2021-08)

Covid-19, healthcare and self-medication issues in resource limited-settings : findings and implications based on experiences in Ghana (2021-09)

Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications (2021-10)

Progress on the national action plan of Pakistan on antimicrobial resistance (AMR): a narrative review and the implications (2022-01)

Biosimilars are essential for sustainable healthcare systems; however, key challenges remain as seen with long-acting insulin analogues (2022-03)

Trends in Antihypertensive Medicine Utilization in the Republic of Srpska, Bosnia and Herzegovina: An Eleven-Year Follow-Up (2022-06)

Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries (2022-06)

Inﬂuence of Recent Initiatives in the Republic of Srpska to Improve Prescribing Efﬁciency; Inﬂuence and Future Direction (2012-08)

Essential To Review Health Policy Initiatives When Comparing Utilisation Patterns across Countries? (2012-08)